[2] 5-MeO-DALT binds to 5-HT1A, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6, α2A, α2B, α2C, H1, κ-opioid, σ1 and σ2 receptors with Ki values lower than 10μM and also acts as a DAT and SERT monoamine reuptake inhibitor.

[4][5] The first material regarding the synthesis and effects of 5-MeO-DALT was sent from Alexander Shulgin to a research associate named Murple in May 2004, after which it was circulated online.

In June 2004 5-MeO-DALT became available from internet research chemical vendors after being synthesized by commercial laboratories in China.

[7] Numerous anecdotal reports[8] and a small-scale trial[9] indicate the potential of 5-MeO-DALT for the treatment of cluster headache, one of the most excruciating conditions known to medicine.

[10] These observations are consistent with evidence of efficacy of other chemically-related indoleamines in the treatment of cluster headache.